Author

I. Ruano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Organism:human· 1

Frequent Co-Authors

N. Prats· 2 shared A. Caballe· 1 shared A. Garcia-Garijo· 1 shared A. Gros· 1 shared A. Henriques· 1 shared A. Riera· 1 shared C. Sanchez-Zarzalejo· 1 shared C. Stephan-Otto Attolini· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

N. Prats

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in mice

D. V. F. Tauriello, E. Sancho, D. Byrom, C. Sanchez-Zarzalejo, M. Salvany, A. Henriques, S. Palomo-Ponce, M. Sevillano, X. Hernando-Momblona, J. A. Matarin, I. Ramos, I. Ruano, N. Prats, E. Batlle, A. Riera

This paper describes the development of HYL001, a TGFβ inhibitor that effectively combats microsatellite stable CRC metastasis in mice when combined with immune checkpoint therapy.

bioRxiv · May 10, 2024 · PreprintPharmacology & Toxicology

Induction of senescence renders cancer cells highly immunogenic

I. Marin, O. Boix, A. Garcia-Garijo, i. Sirois, A. Caballe, E. Zarzuela, I. Ruano, C. Stephan-Otto Attolini, N. Prats, J. A. Lopez-Dominguez, M. Kovatcheva, E. Garralda, J. Munoz, E. Caron, M. Abad, , M. Serrano

This study shows that inducing senescence in cancer cells enhances their immunogenicity, leading to stronger anti-tumor immune responses compared to immunogenic cell death.

bioRxiv · Jun 5, 2022 · PreprintCancer Biology